Medivir - Science working wonders

Improving life for cancer patients

Medivir is a pharmaceutical company focusing on the development of innovative treatments for cancer.

For those most in need

Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.

Our projects >

Partnering for breadth and depth

Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects.

Partnership >

Portfolio highlights

Fostroxacitabine bralpamide (fostrox)

Nucleotide DNA polymerase inhibitor (oral)

More about Fostroxacitabine bralpamide (fostrox)

Birinapant/IGM-9427

SMAC mimetic (intravenous)

More about Birinapant/IGM-9427
View all our current projects

News

2024/04/25

FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease

Read more
2024/04/23

Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue

Read more
2024/04/15

Medivir’s partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701

Read more
See all

Partner with Medivir

Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.

Read more